Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could b...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMC Urol
Huvudupphovsmän: Bibby, Becky A. S., Thiruthaneeswaran, Niluja, Yang, Lingjian, Pereira, Ronnie R., More, Elisabet, McArt, Darragh G., O’Reilly, Paul, Bristow, Robert G., Williams, Kaye J., Choudhury, Ananya, West, Catharine M. L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2021
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247203/
https://ncbi.nlm.nih.gov/pubmed/34210300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-021-00856-x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk